MX2016017094A - Composicion inmunógena de clostridium difficile. - Google Patents
Composicion inmunógena de clostridium difficile.Info
- Publication number
- MX2016017094A MX2016017094A MX2016017094A MX2016017094A MX2016017094A MX 2016017094 A MX2016017094 A MX 2016017094A MX 2016017094 A MX2016017094 A MX 2016017094A MX 2016017094 A MX2016017094 A MX 2016017094A MX 2016017094 A MX2016017094 A MX 2016017094A
- Authority
- MX
- Mexico
- Prior art keywords
- clostridium difficile
- protein
- cdtb
- immunogenic composition
- modify
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000193163 Clostridioides difficile Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108010010925 Clostridium actin-specific ADP-ribosyltransferase Proteins 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción se refiere a composiciones inmunogénicas que comprende las CDTb Clostridium difficile. En particular, la proteína de CDTb Clostridium difficile aislada se ha mutado para modificar la habilidad de formación de poros, para modificar la habilidad de heptamerización o es una proteína CDTb truncada con el péptido señal y el prodominio eliminado y también se eliminó el dominio de unión al receptor y/o se eliminó el dominio de unión a CDTa. La invención también se refiere a proteínas de fusión que comprenden una proteína CDTa y una proteína CDTb. Las vacunas que comprenden dichas composiciones inmunogénicas y usos terapéuticos de las mismas también forman parte de la invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016017094A true MX2016017094A (es) | 2017-05-03 |
| MX374380B MX374380B (es) | 2025-03-06 |
Family
ID=53498986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017094A MX374380B (es) | 2014-06-25 | 2015-06-25 | Composicion inmunógena de clostridium difficile. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (es) |
| EP (2) | EP3160500B1 (es) |
| JP (2) | JP6688233B2 (es) |
| CN (1) | CN106536544B (es) |
| BE (1) | BE1022949B1 (es) |
| BR (1) | BR112016030096B1 (es) |
| CY (1) | CY1122145T1 (es) |
| DK (1) | DK3160500T3 (es) |
| ES (1) | ES2749701T3 (es) |
| HR (1) | HRP20191864T1 (es) |
| HU (1) | HUE045936T2 (es) |
| LT (1) | LT3160500T (es) |
| MX (1) | MX374380B (es) |
| PL (1) | PL3160500T3 (es) |
| PT (1) | PT3160500T (es) |
| SI (1) | SI3160500T1 (es) |
| WO (1) | WO2015197737A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123419B2 (en) | 2017-03-15 | 2021-09-21 | Novavax, Inc. | Methods and compositions for inducing immune responses against Clostridium difficile |
| MX2020013623A (es) | 2018-06-19 | 2021-03-25 | Glaxosmithkline Biologicals Sa | Composicion inmunogenica. |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| JP2851288B2 (ja) | 1987-06-05 | 1999-01-27 | アメリカ合衆国 | 癌診断および管理における自己分泌運動性因子 |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ES2068989T3 (es) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoles como adyuvante en vacunas. |
| UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
| CN1087176C (zh) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | 含有3－o脱酰基单磷酰脂a的疫苗制剂 |
| FI971732A7 (fi) | 1994-10-24 | 1997-06-23 | Ophidian Pharm Inc | Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi j a estämiseksi |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| JPH11506332A (ja) | 1995-06-02 | 1999-06-08 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 全長ｃＤＮＡ配列を獲得する改良された方法 |
| WO2000061762A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| AU2003304316A1 (en) * | 2002-11-08 | 2005-01-28 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| JP6084631B2 (ja) * | 2011-12-08 | 2017-02-22 | ノバルティス アーゲー | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| HUE061273T2 (hu) * | 2012-12-05 | 2023-06-28 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 MX MX2016017094A patent/MX374380B/es active IP Right Grant
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en not_active Ceased
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 HR HRP20191864TT patent/HRP20191864T1/hr unknown
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016030096B1 (pt) | 2023-10-03 |
| PT3160500T (pt) | 2019-11-11 |
| EP3636278A2 (en) | 2020-04-15 |
| JP6688233B2 (ja) | 2020-04-28 |
| CA2952118A1 (en) | 2015-12-30 |
| DK3160500T3 (da) | 2019-11-11 |
| WO2015197737A1 (en) | 2015-12-30 |
| US20170218031A1 (en) | 2017-08-03 |
| BE1022949B1 (fr) | 2016-10-21 |
| CY1122145T1 (el) | 2020-11-25 |
| EP3636278A3 (en) | 2020-07-15 |
| JP2020100625A (ja) | 2020-07-02 |
| BE1022949A1 (fr) | 2016-10-21 |
| MX374380B (es) | 2025-03-06 |
| PL3160500T3 (pl) | 2020-02-28 |
| SI3160500T1 (sl) | 2019-11-29 |
| EP3160500B1 (en) | 2019-08-21 |
| CN106536544B (zh) | 2020-04-07 |
| CN106536544A (zh) | 2017-03-22 |
| BR112016030096A2 (pt) | 2017-08-22 |
| JP2017520573A (ja) | 2017-07-27 |
| EP3160500A1 (en) | 2017-05-03 |
| BR112016030096A8 (pt) | 2021-07-06 |
| HRP20191864T1 (hr) | 2020-01-10 |
| LT3160500T (lt) | 2019-10-25 |
| ES2749701T3 (es) | 2020-03-23 |
| HUE045936T2 (hu) | 2020-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| UY37463A (es) | Proteínas de unión | |
| IL256785A (en) | Chimeric polypeptide assembly and methods of making and using the same | |
| MX421186B (es) | Constructos de anticuerpos. | |
| BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
| MX2016014247A (es) | Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7). | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| MX373277B (es) | Polipeptidos fhbp meningococicos modificados. | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| MX2018000548A (es) | Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana. | |
| BR112017000521A2 (pt) | polipeptídeo, composição imunogênica, e, método para aumentar uma resposta ao anticorpo. | |
| BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
| MX382535B (es) | Proteinas de fusion fmdv y e2 y usos de ellos. | |
| IL275435B (en) | tatk-cdkl5 fusion proteins, preparations, formulations, and their uses | |
| MX382409B (es) | Variantes de proteinas de unión al factor h y métodos de uso de estas. | |
| DK3146042T3 (da) | Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop | |
| IL263842A (en) | Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| ECSP19008417A (es) | Anticuerpos con inmunogenicidad baja y usos de estos | |
| BR112015023738B8 (pt) | Vacinas de nucleoproteina influenza | |
| MX392514B (es) | Vacuna para estreptococo del grupo a. | |
| MX2016017094A (es) | Composicion inmunógena de clostridium difficile. | |
| EP3125923A4 (en) | Lyophilized pharmaceutical composition of fc-peptide fusion protein | |
| BR112016019390A2 (pt) | proteínas de fusão uti |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |